Point Of Care Diagnostics & Testing Market Competitive Analysis And ForecastPosted by Neha Bora on February 1st, 2021 San Francisco, 1 Feb 2021: The Report Point Of Care Diagnostics & Testing Market Size, Share & Trends Analysis Report By Product (Infectious Diseases, Cancer Marker), By End-use (Home, Clinics), By Region, And Segment Forecasts, 2021 - 2028 The global point of care diagnostics & testing market size is estimated to reach USD 35.74 billion by 2028, registering a CAGR of 3.25%, according to a new report by Grand View Research, Inc. Point of care (POC) diagnostics & testing has significantly altered the therapeutic models applied for the treatment of diabetic patients, HIV patients, and patients with Cardiovascular Disorders (CVDs), in recent years. In addition, emerging advancements on the horizon are projected to enhance the near-patient treatment workflows for infectious diseases, strokes, and cancer. The industry is set to witness lucrative growth as POC testing serves as a profitable alternative to traditional laboratory tests. Point-of-care devices are designed to offer actionable information at the location and time of patient care, which enables early diagnosis of diseases. The advent of non-invasive & minimally invasive POC devices, continuous POCT, miniaturized technologies, and the adoption of telemedicine in remote patient monitoring are some of the key trends contributing to the market growth. Moreover, the advent of rapid data sharing solutions as well as platforms is set to contribute to the development of POC COVID-19 tests, supplementing the overall market growth. Companies actively working toward the development of such rapid data sharing solutions include Foundation for Innovative New Diagnostics (FIND) and 360 Dx. The rising number of such companies is set to offer manufacturers/developers and professionals a clear perspective with respect to the future opportunities associated with POC COVID-19 tests. The development of multiplex POC diagnostic technologies that enable the detection of multiple infectious pathogens in specimens, such as sputum, urine, or blood, offers improved patient outcomes and better disease diagnosis. The wide adoption of multiplex POC devices is anticipated to serve as a driver for the shift in preference from a centralized disease testing model to a decentralized patient-centered model. Major companies are initiating strategic product launches to strengthen their market presence. For instance, in October 2020, Roche announced the launch of the Elecsys SARS-CoV-2 Antigen test that supports COVID-19 testing of suspected patients at high volumes. In April 2020, Nova Biomedical introduced PT/INR testing for its Allegro capillary blood analyzer to be used in POC primary care settings. This test is available in CE-regulated countries. PR/INR is among the total 18 tests of the Allegro platform and is designed to measure HbA1c, hemoglobin, cholesterol, glucose, triglycerides, UACR, creatinine, hematocrit, and uric acid. This product expanded the testing portfolio of the company’s Allergo platform. Access Research Report of Point Of Care Diagnostics & Testing Market @ https://www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry Point of Care Diagnostics & Testing Market Report Highlights
List of Key Players of POC Diagnostics & Testing Market
Like it? Share it!More by this author |